Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease
Ellen Bradley, Parker Kelley, Balázs Szigeti, Kristen Nishimi, Martin Picard, Kimberly Sakai, Gisele Fernandes-Osterhold, Jill L Ostrem, Caroline M Tanner, Connie Ludwig, Katiah Llerena, Patrick R Finley, Zachary Busby, Amber McKernan, Madeline Marie Pantoni, Andrew Penn, Aliss C C Wang, Jose Rafael Pantoja Zuzuarregui, Joshua Woolley, Aoife O’donovan
JAMA Psychiatry October 21, 2026 DOI: 10.1001/jamapsychiatry.2026.2733 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized Peer reviewed |
|---|---|
| Topics | Psilocybin |
Abstract
This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.